Venous Thromboembolism Market Size, Share, Growth, Trends And Forecast 2024-2033

Posted April 2, 2024 by Shraddhatbrc

Global venous thromboembolism size is expected at $2.87 Bn by 2028 at a growth rate of 4.2% and trends by The Business Research Company.
Overview and Scope
Venous thromboembolism (VTE) refers to a medical condition characterized by the formation of blood clots within the veins, which can lead to potentially serious or life-threatening complications. common symptoms of VTE include leg pain and swelling, rapid breathing, chest pain and more. The various treatment methods, such as anticoagulant medications, devices and thrombolytic therapy, are used for the treatment of VTE.

Sizing and Forecast
The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.33 billion in 2023 to $2.44 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population, advancements in anticoagulants, reimbursement policies, increasing investments.

The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $2.87 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to global healthcare access, genetic risk assessment, telemedicine and remote monitoring, patient education and support. Major trends in the forecast period include extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, advanced diagnostic imaging.

To access more details regarding this report, visit the link:

Segmentation & Regional Insights
The venous thromboembolism market covered in this report is segmented –
1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types
2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment
3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users

North America was the largest region in the venous thromboembolism market in 2023. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

Major Driver Impacting Market Growth
The expansion of the healthcare infrastructure is expected to propel the growth of the venous thromboembolism market going forward. The healthcare industry refers to amalgamating and integrating the economic system's sectors that offer products and services for curing, preventing, rehabilitating and providing palliative care for patients. The expansion of the healthcare industry contributes to the development of Institutional infrastructure, policies, practices and educational programs necessary to support the implementation of VTE prevention protocols. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the US increased to 6,129 from 6,093 in 2022. Furthermore, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2020 and 2021, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms. Therefore, the expansion of the healthcare industry is driving the growth of the venous thromboembolism market.

Key Industry Players
Major players in the venous thromboembolism market are  Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

The venous thromboembolism market report table of contents includes:
1. Executive Summary
2. Venous Thromboembolism Market Characteristics
3. Venous Thromboembolism Market Trends And Strategies
4. Venous Thromboembolism Market - Macro Economic Scenario
5. Global Venous Thromboembolism Market Size and Growth
32. Global Venous Thromboembolism Market Competitive Benchmarking
33. Global Venous Thromboembolism Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Venous Thromboembolism Market
35. Venous Thromboembolism Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
Healthcare Blog:
Global Market Model:
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Shraddha
Country United States
Categories Health , Medical , Reports
Tags venous thromboembolism market , venous thromboembolism market size , venous thromboembolism market share , venous thromboembolism market growth , venous thromboembolism market analysis
Last Updated April 2, 2024